The Trump administration announced Thursday its intention to address microplastics and pharmaceuticals in U.S. drinking water. Environmental Protection Agency (EPA) Administrator Lee Zeldin stated at a Washington news conference that the agency plans to propose adding these substances to a list of priority pollutants.

This move could facilitate increased federal research into their prevalence, health impacts, and removal methods, potentially leading to new treatment standards for water utilities. Mr. Zeldin called the initiative "a landmark set of actions," responding to public concern over water safety. The EPA is accepting public comments on its proposal for 60 days.

Health Secretary Robert F. Kennedy Jr., who joined Mr. Zeldin, announced $144 million in federal funding for research into microplastics in the human body. Supporters of the Make America Healthy Again (MAHA) movement, a key segment of President Trump’s base, welcomed the plan. Vani Hari, a prominent MAHA activist, highlighted the importance of officially tracking these substances for regulatory purposes, despite recent MAHA criticism of the administration's glyphosate policy.

However, environmental groups and experts expressed skepticism. Erik D. Olson, senior director for environmental health at the Natural Resources Defense Council, dismissed the announcement as "smoke and mirrors," pointing to the administration's past failure to regulate new chemicals from a priority list and its rollback of PFAS drinking water standards.

Experts cautioned that designating these substances as priority pollutants is merely the initial step in a multi-year process, which may not ultimately result in new regulations. Vasilis Vasiliou, chair of Environmental Health Sciences at Yale University, noted the significant scientific work required for assessment, potentially burdening an EPA with staffing levels at a 40-year low.

Scientific challenges are substantial. For microplastics, tiny plastic fragments from everyday products, no standardized measurement method exists due to their varied properties. While detected in human and animal tissues, their health effects remain under investigation. Animal studies suggest harm to reproduction and increased cancer risk, and human studies indicate associations with cardiovascular disease, dementia, and preterm births, though causality is unproven.

Pharmaceuticals, including painkillers and antibiotics, also appear in water supplies. Although generally at levels not toxic to humans, they can affect aquatic life, with lab tests showing accumulation in fish brains impacting mating behavior. Developing appropriate limits for diverse pharmaceuticals is complex, complicated by drug interactions and the ongoing development of methods to assess mixed toxicity, according to Diana S. Aga, chair of chemistry at the University at Buffalo.

EPA spokeswoman Carolyn Holran said the agency is coordinating with partners, the public, and MAHA leaders, planning to release a comprehensive "MAHA agenda" soon. This initiative aligns with broader efforts to engage with this vocal segment of the president's base, which has also demanded an emergency review of pesticides and a halt to new plastic manufacturing approvals.